Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells
Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor microenvironment. Cav-1 is highly expressed in adipocytes and is abundant in mammary fat pads (stroma), but it remains unknown whether loss of Ca...
Saved in:
| Published in: | The American journal of pathology Vol. 169; no. 5; p. 1784 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.11.2006
|
| Subjects: | |
| ISSN: | 0002-9440 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor microenvironment. Cav-1 is highly expressed in adipocytes and is abundant in mammary fat pads (stroma), but it remains unknown whether loss of Cav-1 within mammary stromal cells affects the differentiated state of mammary epithelia via paracrine signaling. To address this issue, we characterized the development of the mammary ductal system in Cav-1-/- mice and performed a series of mammary transplant studies, using both wild-type and Cav-1-/- mammary fat pads. Cav-1-/- mammary epithelia were hyperproliferative in vivo, with dramatic increases in terminal end bud area and mammary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-regulated kinase-1/2 hyperactivation, and up-regulation of STAT5a and cyclin D1. Consistent with these findings, loss of Cav-1 dramatically exacerbated mammary lobulo-alveolar hyperplasia in cyclin D1 Tg mice, whereas overexpression of Cav-1 caused reversion of this phenotype. Most importantly, Cav-1-/- mammary stromal cells (fat pads) promoted the growth of both normal mammary ductal epithelia and mammary tumor cells. Thus, Cav-1 expression in both epithelial and stromal cells provides a protective effect against mammary hyperplasia as well as mammary tumorigenesis. |
|---|---|
| AbstractList | Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor microenvironment. Cav-1 is highly expressed in adipocytes and is abundant in mammary fat pads (stroma), but it remains unknown whether loss of Cav-1 within mammary stromal cells affects the differentiated state of mammary epithelia via paracrine signaling. To address this issue, we characterized the development of the mammary ductal system in Cav-1-/- mice and performed a series of mammary transplant studies, using both wild-type and Cav-1-/- mammary fat pads. Cav-1-/- mammary epithelia were hyperproliferative in vivo, with dramatic increases in terminal end bud area and mammary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-regulated kinase-1/2 hyperactivation, and up-regulation of STAT5a and cyclin D1. Consistent with these findings, loss of Cav-1 dramatically exacerbated mammary lobulo-alveolar hyperplasia in cyclin D1 Tg mice, whereas overexpression of Cav-1 caused reversion of this phenotype. Most importantly, Cav-1-/- mammary stromal cells (fat pads) promoted the growth of both normal mammary ductal epithelia and mammary tumor cells. Thus, Cav-1 expression in both epithelial and stromal cells provides a protective effect against mammary hyperplasia as well as mammary tumorigenesis.Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor microenvironment. Cav-1 is highly expressed in adipocytes and is abundant in mammary fat pads (stroma), but it remains unknown whether loss of Cav-1 within mammary stromal cells affects the differentiated state of mammary epithelia via paracrine signaling. To address this issue, we characterized the development of the mammary ductal system in Cav-1-/- mice and performed a series of mammary transplant studies, using both wild-type and Cav-1-/- mammary fat pads. Cav-1-/- mammary epithelia were hyperproliferative in vivo, with dramatic increases in terminal end bud area and mammary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-regulated kinase-1/2 hyperactivation, and up-regulation of STAT5a and cyclin D1. Consistent with these findings, loss of Cav-1 dramatically exacerbated mammary lobulo-alveolar hyperplasia in cyclin D1 Tg mice, whereas overexpression of Cav-1 caused reversion of this phenotype. Most importantly, Cav-1-/- mammary stromal cells (fat pads) promoted the growth of both normal mammary ductal epithelia and mammary tumor cells. Thus, Cav-1 expression in both epithelial and stromal cells provides a protective effect against mammary hyperplasia as well as mammary tumorigenesis. Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor microenvironment. Cav-1 is highly expressed in adipocytes and is abundant in mammary fat pads (stroma), but it remains unknown whether loss of Cav-1 within mammary stromal cells affects the differentiated state of mammary epithelia via paracrine signaling. To address this issue, we characterized the development of the mammary ductal system in Cav-1-/- mice and performed a series of mammary transplant studies, using both wild-type and Cav-1-/- mammary fat pads. Cav-1-/- mammary epithelia were hyperproliferative in vivo, with dramatic increases in terminal end bud area and mammary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-regulated kinase-1/2 hyperactivation, and up-regulation of STAT5a and cyclin D1. Consistent with these findings, loss of Cav-1 dramatically exacerbated mammary lobulo-alveolar hyperplasia in cyclin D1 Tg mice, whereas overexpression of Cav-1 caused reversion of this phenotype. Most importantly, Cav-1-/- mammary stromal cells (fat pads) promoted the growth of both normal mammary ductal epithelia and mammary tumor cells. Thus, Cav-1 expression in both epithelial and stromal cells provides a protective effect against mammary hyperplasia as well as mammary tumorigenesis. |
| Author | Capozza, Franco Lee, Hyangkyu Di Vizio, Dolores Pestell, Richard G Williams, Terence M Sotgia, Federica Mercier, Isabelle Rui, Hallgeir Lisanti, Michael P Hassan, Ghada Bonuccelli, Gloria |
| Author_xml | – sequence: 1 givenname: Terence M surname: Williams fullname: Williams, Terence M organization: Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA – sequence: 2 givenname: Federica surname: Sotgia fullname: Sotgia, Federica – sequence: 3 givenname: Hyangkyu surname: Lee fullname: Lee, Hyangkyu – sequence: 4 givenname: Ghada surname: Hassan fullname: Hassan, Ghada – sequence: 5 givenname: Dolores surname: Di Vizio fullname: Di Vizio, Dolores – sequence: 6 givenname: Gloria surname: Bonuccelli fullname: Bonuccelli, Gloria – sequence: 7 givenname: Franco surname: Capozza fullname: Capozza, Franco – sequence: 8 givenname: Isabelle surname: Mercier fullname: Mercier, Isabelle – sequence: 9 givenname: Hallgeir surname: Rui fullname: Rui, Hallgeir – sequence: 10 givenname: Richard G surname: Pestell fullname: Pestell, Richard G – sequence: 11 givenname: Michael P surname: Lisanti fullname: Lisanti, Michael P |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17071600$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1OwzAQhH0AQQu8AAfkE7cUJ06dmhsqv1IlDsC5WifrxlVih9ipVB6M58MFKjjtzmr0aXbG5MA6i4Scp2yS8Sm_gnUHoZ5kjIkJE2wq2QEZMcayROY5OyZj79dRCj5jR-Q4LViRCsZG5PMl9K6FhoKtKHYm1NiYKEvYoGuMTVKqXKhp6azGngLtehewDGaDFLWOG4UVGOsDbaFtod_Setth3zXgDXxTw9C63qzQojf-ms7_yGADrJw1H-hpuS3jkd6mVA828p2lUe6Z_5Nh0_hTcqih8Xj2O0_I2_3d6_wxWTw_PM1vFknNMxESLoDpPFczmRdSI9eVQg1aFUrJXIOUwKUqAXRWFlU5m4LgWSU4FJpxVaDITsjlDze-_T6gD8vW-F0CsOgGvxQyVsyneTRe_BoH1WK17HqzC77cN519AdDFh2c |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2353/ajpath.2006.060590 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 17071600 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01CA93596 – fundername: NCI NIH HHS grantid: R01 CA080250 – fundername: NCI NIH HHS grantid: R01CA80250 – fundername: NCI NIH HHS grantid: R01 CA093596 – fundername: NCI NIH HHS grantid: R01 CA098779 – fundername: NCI NIH HHS grantid: R01CA98779 |
| GroupedDBID | --- --K -~X .1- .55 .FO .GJ 0R~ 1P~ 23M 2WC 34R 3O- 3V. 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 7X7 88E 88I 8AF 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AACTN AAEDT AAEDW AAIKJ AALRI AAQFI AAQXK AAXUO ABCQX ABJNI ABLJU ABMAC ABOCM ABUWG ABWVN ACGFO ACGOD ACPRK ACRPL ADBBV ADEZE ADHJS ADMUD ADNMO ADPAM ADVLN AENEX AEVXI AFCTW AFFNX AFJKZ AFKRA AFRHN AFTJW AGHFR AHDRD AHMBA AI. AITUG AJUYK AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BELOY BENPR BHPHI BPHCQ BVXVI C1A CCPQU CGR CS3 CUY CVF DIK DWQXO E3Z EBS ECM EFJIC EIF EJD F5P FDB FEDTE FGOYB FYUFA GBLVA GNUQQ GX1 H13 HCIFZ HMCUK HVGLF HX~ HZ~ IH2 IXB J5H KOM KQ8 L7B LID LK8 M1P M2P M41 M7P MVM N9A NPM O9- OG~ OHT OK1 OS. P2P PQQKQ PROAC PSQYO Q2X R2- ROL RPM SEL SES SJN SSZ TIP TR2 UKHRP VH1 VXZ WH7 WOQ X7M XH2 Y6R YHG YNH Z5R ZGI ZXP 7X8 AAFWJ ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-h326t-36a0f44b89479fe3fdbefafb7bb94fa99a39bcaaf2c7dc85a632d63a7f03b7e62 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 76 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000241603700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0002-9440 |
| IngestDate | Thu Oct 02 11:05:08 EDT 2025 Wed Feb 19 01:45:48 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-h326t-36a0f44b89479fe3fdbefafb7bb94fa99a39bcaaf2c7dc85a632d63a7f03b7e62 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 17071600 |
| PQID | 69002354 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_69002354 pubmed_primary_17071600 |
| PublicationCentury | 2000 |
| PublicationDate | 2006-11-01 |
| PublicationDateYYYYMMDD | 2006-11-01 |
| PublicationDate_xml | – month: 11 year: 2006 text: 2006-11-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The American journal of pathology |
| PublicationTitleAlternate | Am J Pathol |
| PublicationYear | 2006 |
| References | 12004111 - Science. 2002 May 10;296(5570):1046-9 11733547 - J Clin Invest. 2001 Dec;108(11):1553-61 2011398 - Oncogene. 1991 Mar;6(3):439-44 10748172 - J Biol Chem. 2000 Jul 7;275(27):20717-25 15331580 - Endocrinology. 2004 Dec;145(12):5439-47 9525738 - Oncogene. 1998 Mar;16(11):1391-7 7587110 - Cold Spring Harb Symp Quant Biol. 1994;59:537-46 15383654 - Physiol Rev. 2004 Oct;84(4):1341-79 11739396 - J Biol Chem. 2002 Mar 8;277(10):8635-47 12368209 - Am J Pathol. 2002 Oct;161(4):1357-69 9361015 - J Biol Chem. 1997 Nov 14;272(46):29337-46 12223531 - Pharmacol Rev. 2002 Sep;54(3):431-67 11602600 - J Biol Chem. 2001 Dec 21;276(51):48389-97 13663040 - Cancer Res. 1959 Jun;19(5):515-20 16510571 - Cancer Res. 2006 Mar 1;66(5):2544-52 11429595 - Nature. 2001 Jun 28;411(6841):1017-21 11289096 - Cancer Res. 2001 Mar 15;61(6):2361-4 16809779 - Mol Cell Biol. 2006 Jul;26(14):5449-69 8939849 - Science. 1996 Dec 6;274(5293):1672-7 15003112 - Genome Biol. 2004;5(3):214 8663016 - J Biol Chem. 1996 Jun 21;271(25):15160-5 14508521 - Oncogene. 2003 Sep 25;22(41):6408-23 10611246 - Mol Cell Biol. 2000 Jan;20(2):672-83 15355971 - J Biol Chem. 2004 Dec 3;279(49):51630-46 16418573 - Cancer Biol Ther. 2006 Mar;5(3):292-7 10747899 - J Biol Chem. 2000 Jul 14;275(28):21203-9 8168995 - Int J Cancer. 1994 May 1;57(3):353-61 9488658 - J Biol Chem. 1998 Mar 6;273(10):5419-22 12352463 - J Urol. 2002 Oct;168(4 Pt 1):1589-96 8137296 - Cancer Res. 1994 Apr 1;54(7):1812-7 10458605 - Cell. 1999 Aug 6;98(3):295-303 10064602 - EMBO J. 1999 Mar 1;18(5):1367-77 1312220 - Mol Cell Biol. 1992 Mar;12(3):954-61 8567687 - J Biol Chem. 1996 Jan 26;271(4):2255-61 9685399 - J Biol Chem. 1998 Aug 7;273(32):20448-55 14578209 - Am J Pathol. 2003 Nov;163(5):2113-26 15334058 - Oncogene. 2004 Oct 14;23(47):7893-7 11948420 - Oncogene. 2002 Apr 4;21(15):2365-75 14731661 - Trends Cell Biol. 1994 Jul;4(7):231-5 8208295 - Nature. 1994 Jun 23;369(6482):669-71 7675778 - Mod Pathol. 1995 Jun;8(5):560-7 9717814 - Clin Cancer Res. 1998 Aug;4(8):1873-80 11719463 - Cancer Res. 2001 Nov 15;61(22):8298-305 16294019 - Cell Cycle. 2005 Dec;4(12):1808-16 10218480 - FEBS Lett. 1999 Apr 9;448(2-3):221-30 12388746 - Mol Biol Cell. 2002 Oct;13(10):3416-30 12631721 - Mol Biol Cell. 2003 Mar;14(3):1027-42 11514613 - Mol Biol Cell. 2001 Aug;12(8):2229-44 |
| References_xml | – reference: 8168995 - Int J Cancer. 1994 May 1;57(3):353-61 – reference: 11719463 - Cancer Res. 2001 Nov 15;61(22):8298-305 – reference: 12352463 - J Urol. 2002 Oct;168(4 Pt 1):1589-96 – reference: 9717814 - Clin Cancer Res. 1998 Aug;4(8):1873-80 – reference: 14731661 - Trends Cell Biol. 1994 Jul;4(7):231-5 – reference: 12368209 - Am J Pathol. 2002 Oct;161(4):1357-69 – reference: 10747899 - J Biol Chem. 2000 Jul 14;275(28):21203-9 – reference: 15334058 - Oncogene. 2004 Oct 14;23(47):7893-7 – reference: 11739396 - J Biol Chem. 2002 Mar 8;277(10):8635-47 – reference: 7675778 - Mod Pathol. 1995 Jun;8(5):560-7 – reference: 11514613 - Mol Biol Cell. 2001 Aug;12(8):2229-44 – reference: 15383654 - Physiol Rev. 2004 Oct;84(4):1341-79 – reference: 8663016 - J Biol Chem. 1996 Jun 21;271(25):15160-5 – reference: 9361015 - J Biol Chem. 1997 Nov 14;272(46):29337-46 – reference: 10064602 - EMBO J. 1999 Mar 1;18(5):1367-77 – reference: 9685399 - J Biol Chem. 1998 Aug 7;273(32):20448-55 – reference: 8137296 - Cancer Res. 1994 Apr 1;54(7):1812-7 – reference: 11948420 - Oncogene. 2002 Apr 4;21(15):2365-75 – reference: 12631721 - Mol Biol Cell. 2003 Mar;14(3):1027-42 – reference: 12004111 - Science. 2002 May 10;296(5570):1046-9 – reference: 12223531 - Pharmacol Rev. 2002 Sep;54(3):431-67 – reference: 14508521 - Oncogene. 2003 Sep 25;22(41):6408-23 – reference: 10611246 - Mol Cell Biol. 2000 Jan;20(2):672-83 – reference: 15003112 - Genome Biol. 2004;5(3):214 – reference: 10458605 - Cell. 1999 Aug 6;98(3):295-303 – reference: 11602600 - J Biol Chem. 2001 Dec 21;276(51):48389-97 – reference: 11733547 - J Clin Invest. 2001 Dec;108(11):1553-61 – reference: 1312220 - Mol Cell Biol. 1992 Mar;12(3):954-61 – reference: 10748172 - J Biol Chem. 2000 Jul 7;275(27):20717-25 – reference: 2011398 - Oncogene. 1991 Mar;6(3):439-44 – reference: 11429595 - Nature. 2001 Jun 28;411(6841):1017-21 – reference: 12388746 - Mol Biol Cell. 2002 Oct;13(10):3416-30 – reference: 11289096 - Cancer Res. 2001 Mar 15;61(6):2361-4 – reference: 10218480 - FEBS Lett. 1999 Apr 9;448(2-3):221-30 – reference: 16294019 - Cell Cycle. 2005 Dec;4(12):1808-16 – reference: 8939849 - Science. 1996 Dec 6;274(5293):1672-7 – reference: 7587110 - Cold Spring Harb Symp Quant Biol. 1994;59:537-46 – reference: 15355971 - J Biol Chem. 2004 Dec 3;279(49):51630-46 – reference: 8567687 - J Biol Chem. 1996 Jan 26;271(4):2255-61 – reference: 9488658 - J Biol Chem. 1998 Mar 6;273(10):5419-22 – reference: 9525738 - Oncogene. 1998 Mar;16(11):1391-7 – reference: 16510571 - Cancer Res. 2006 Mar 1;66(5):2544-52 – reference: 16418573 - Cancer Biol Ther. 2006 Mar;5(3):292-7 – reference: 15331580 - Endocrinology. 2004 Dec;145(12):5439-47 – reference: 16809779 - Mol Cell Biol. 2006 Jul;26(14):5449-69 – reference: 13663040 - Cancer Res. 1959 Jun;19(5):515-20 – reference: 8208295 - Nature. 1994 Jun 23;369(6482):669-71 – reference: 14578209 - Am J Pathol. 2003 Nov;163(5):2113-26 |
| SSID | ssj0006380 |
| Score | 2.1584902 |
| Snippet | Here, we investigate the role of caveolin-1 (Cav-1) in breast cancer onset and progression, with a focus on epithelial-stromal interactions, ie, the tumor... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1784 |
| SubjectTerms | Adipose Tissue - cytology Adipose Tissue - pathology Animals Caveolin 1 - deficiency Caveolin 1 - metabolism Cell Proliferation Cyclin D1 - antagonists & inhibitors Cyclin D1 - metabolism Enzyme Activation Epithelial Cells - cytology Female Hyperplasia Male Mammary Glands, Animal - pathology Mammary Neoplasms, Animal - chemically induced Mammary Neoplasms, Animal - pathology Mammary Tumor Virus, Mouse Mice Mice, Knockout Mitogen-Activated Protein Kinase 1 - metabolism Mitogen-Activated Protein Kinase 3 - metabolism Phenotype Protective Agents - metabolism Signal Transduction STAT5 Transcription Factor - metabolism Stromal Cells - cytology |
| Title | Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17071600 https://www.proquest.com/docview/69002354 |
| Volume | 169 |
| WOSCitedRecordID | wos000241603700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3685eC12m2zTiiDiAy8uggp7WyZp4q7sdtftKugP8_c5SVv0Ih68FArtMDBfJl8e3wxjR5oIG0dhAqV4GIhEqyCJLa15ZKZ5xqWJjfDNJmSrlbTb6d0UO621MO5aZZ0TfaLOhtrtkR_TKs6VZhFno5fA9YxyZ6tVA41pNsuJyDhMy_Z3rXBCVliT31SIsJTMkA1-jM-u3291FBE7_eXvBNNPNNdL_3NxmS1WBBPOS0SssCmTr7L52-oIfY193k_GwwF9gXkGZuQkGX3CIGh8M66BT9AARdED7aWAgFBVcqCsCOXlD8An7BGrhAF64Rt0aS07Hnk9prc6eR04x1wW7RUncPFtmcKIT5RFPkwB-t2pMuGyAW5udfgAeq1t_vTM9PvFOnu8vnq4uAmq5g1BlxjhJOAxhlYIlaRCptZwmylj0SqpVCospinyVGlEG2mCRdLEmEdZzFHakCuCSLTBZvJhbrYYRMISr1PNCKNMmFigEFwSkpCimmETt9lhHY8ODQ7nFeZm-Fp06ohss80ypJ1RWcOj05DErYjs7fz57y5b8NsuXn-4x2YtpQWzz-b026RXjA885ujZurv9AkXG5z4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stromal+and+epithelial+caveolin-1+both+confer+a+protective+effect+against+mammary+hyperplasia+and+tumorigenesis%3A+Caveolin-1+antagonizes+cyclin+D1+function+in+mammary+epithelial+cells&rft.jtitle=The+American+journal+of+pathology&rft.au=Williams%2C+Terence+M&rft.au=Sotgia%2C+Federica&rft.au=Lee%2C+Hyangkyu&rft.au=Hassan%2C+Ghada&rft.date=2006-11-01&rft.issn=0002-9440&rft.volume=169&rft.issue=5&rft.spage=1784&rft_id=info:doi/10.2353%2Fajpath.2006.060590&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0002-9440&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0002-9440&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0002-9440&client=summon |